One donor, two transplants: could this end lifelong Anti-Rejection drugs?
NCT ID NCT01758042
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection drugs. Participants received a milder chemotherapy and radiation regimen to lower side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Combined bone marrow and kidney transplant from a partially matched related donor
- What this could lead to
- If successful, this approach could reduce the need for lifelong anti-rejection drugs after kidney transplant and treat both the blood disorder and kidney disease in one procedure.
- What could go wrong
- This is a very small pilot study with only 10 participants, so results may not apply broadly. The procedure carries serious risks including infection, graft-versus-host disease, and treatment-related death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Aging kidneys under the microscope: could a simple test predict failure?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can 3D-Printed models unlock personalized blood cancer therapies?